Vol.58 No.3 May 2010
Clinical efficacy of amoxicillin, cefcapene-pivoxil, or faropenem for treatment respiratory infection in children: a multicentric randomised controlled trial
Department of Pediatrics, Asahikawa Kosei Hospital, 1-24 Asahikawa, Hokkaido, Japan
Abstract
In order to compare bacteriological and clinical efficacies, ease of drug ingestion and the safety of amoxicillin(AMPC) 30-40 mg/kg/day, cefcapene-pivoxil(CFPN-PI) 9 mg/kg/day, and faropenem(FRPM) 15 mg/kg/day for the treatment of bacterial respiratory infections in children, a prospective multicenter randomized open-label comparative study was performed in 10 pediatric clinics in Hokkaido between October 2008 and March 2009. Out of 212 children enrolled in this study, 198 including 105 with pneumonia/bronchitis, 88 with pharyngitis/tonsillitis, and 5 with acute otitis media were evaluated for clinical efficacy. Efficacy rates for pneumonia/bronchitis were 91.2% in the AMPC group, 90.9% in the CFPN-PI group, and 94.7% in the FRPM group and those for pharyngitis/tonsillitis were 100%, 96.8% and 96.7%, respectively. For streptococcal infection, the AMPC, CFPN-PI and FRPM groups showed bacteriological eradication rates at the end of 4 to 6 day treatment of 100%, 100% and 71.4%, respectively (p=0.011). Eradication rates with 7 to 10 day treatment were 88.9%, 75.0% and 70.0%, respectively. The rate of ease of FRPM ingestion was significantly higher than those of AMPC and CFPN-PI (p<0.001). The adverse effects were diarrhea in all three groups; 13.6% in the AMPC group, 7.6% in the CFPN-PI group, and 13.9% the FRPM group.
Key word
amoxicillin, cefcapene-pivoxil, faropenem, pneumonia, child, respiratory tract infection(RTI)
Received
January 12, 2010
Accepted
April 5, 2010
Jpn. J. Chemother. 58 (3): 239-247, 2010
